Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2003

View Archived Issues

Ganstigmine safe in patients with probable Alzheimer's disease

NSAIDs evaluated for slowing the progression of Alzheimer's disease

Low response rate for SU-5416 in refractory myeloproliferative disorders

Improved glycemic control reported for nateglinide plus rosiglitazone in type 2 diabetes

Apafant effective in UVB-induced dermatitis

Wyeth claims three series of ERbeta-selective estrogenic agents for arthritis, IBD, etc.

Plant extract with gastric antisecretory activity patented by Korean researchers

Novel bone antiresorptive agents covered by Sankyo patent

New tachykinin NK1 antagonists prepared and tested at Schering-Plough

Novo Nordisk scientists present new glucagon antagonists/inverse agonists in recent patent

Roche describes new inhibitors of MDM2/p53 interaction with utility in cancer

Novel protein kinase inhibitors in early development at Abbott

South Korean scientists report synthesis and biological evaluation of promising antitumor retinoid

Caspase-dependent cell-killing and TRAIL-sensitizing effects reported for estrogen derivative

Discovery of potent, orally active, irreversible Her-2 receptor tyrosine kinase inhibitor reported

A-409100, a second-generation FTase inhibitor with a promising preclinical profile

Selective chemotherapy with SDX-102 in MTAP-deficient tumors

Positive safety results emerge from phase I/II study of Theralux

4SC and Esteve broaden their research partnership

AMD-3100 granted orphan drug status for stem cell transplantation in cancer patients

Boehringer Ingelheim and Medivir sign agreement for MIV-310

FDA advisory panel to review Onyx for the treatment of certain neurovascular disorders

Roche SARS test now available

Curacyte discovers new antitumor agents

Antiangiogenic/antitumor VEGFR kinase inhibitor with an anthranilamide structure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...